Etanercept TNF Inhibitor
Recombinant TNF receptor fusion protein for psoriasis and arthritis. Immunological product 3002.90.52.50.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Receptor binding assays
• Auto-injector validation
Related Products under HTS 3002.90.52.50
Human Serum Albumin USP 25% Solution
A sterile solution of human serum albumin at 25% concentration, prepared from human plasma for therapeutic use in treating hypovolemia and shock. It falls under HTS 3002.90.52.50 as a blood fraction prepared for therapeutic use, derived from human blood through fractionation processes. This immunological product supports plasma volume expansion in clinical settings.
IVIG Intravenous Immunoglobulin 10% Infusion
A pooled immunoglobulin G preparation from human plasma, used therapeutically for primary immunodeficiency and autoimmune disorders. Classified under HTS 3002.90.52.50 as an immunological product and blood fraction obtained via biotechnological purification. It modulates immune responses in patients with antibody deficiencies.
Monoclonal Antibody Infliximab Biosimilar
A recombinant chimeric monoclonal antibody targeting TNF-alpha, used for treating inflammatory conditions like rheumatoid arthritis. It qualifies under HTS 3002.90.52.50 as an immunological product directly involved in immune regulation, produced via biotechnological processes. Administered intravenously for therapeutic purposes.
Interferon Beta-1a Injection for MS
A recombinant interferon beta-1a formulation for relapsing multiple sclerosis treatment, regulating immune processes. Falls under HTS 3002.90.52.50 as an immunological product (interferon) prepared for therapeutic use via biotechnological methods. It reduces disease activity in neurological conditions.
Recombinant Human Erythropoietin Alfa
A biotechnologically produced hematopoietin stimulating red blood cell production, used in anemia treatment for chronic kidney disease patients. Classified in HTS 3002.90.52.50 as an immunological product (hematopoietin) for therapeutic use. It is a growth factor directly involved in blood cell regulation.
Anti-Hemophilic Factor VIII Concentrate
A plasma-derived or recombinant Factor VIII concentrate for preventing bleeding in hemophilia A patients. It is a blood fraction and immunological product under HTS 3002.90.52.50, prepared for therapeutic prophylactic use. Essential for clotting factor replacement therapy.